WO2015079420A3 - Composition vaccinale pour la prevention et/ou le traitement de leishmanioses, peptides immunogenes et procede d'obtention - Google Patents

Composition vaccinale pour la prevention et/ou le traitement de leishmanioses, peptides immunogenes et procede d'obtention Download PDF

Info

Publication number
WO2015079420A3
WO2015079420A3 PCT/IB2014/066425 IB2014066425W WO2015079420A3 WO 2015079420 A3 WO2015079420 A3 WO 2015079420A3 IB 2014066425 W IB2014066425 W IB 2014066425W WO 2015079420 A3 WO2015079420 A3 WO 2015079420A3
Authority
WO
WIPO (PCT)
Prior art keywords
preventing
vaccine composition
immunogenic peptides
obtaining same
psa
Prior art date
Application number
PCT/IB2014/066425
Other languages
English (en)
Other versions
WO2015079420A2 (fr
Inventor
Jean-Loup Lemesre
Gérard-Marie PAPIEROK
Rachel Elise BRAS GONCALVES
Elodie PETITDIDIER-LESIN
Original Assignee
Institut De La Recherche Pour Le Developpement (Ird)
Virbac
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut De La Recherche Pour Le Developpement (Ird), Virbac filed Critical Institut De La Recherche Pour Le Developpement (Ird)
Priority to EP14830587.3A priority Critical patent/EP3074418A2/fr
Priority to BR112016012097-3A priority patent/BR112016012097A2/pt
Publication of WO2015079420A2 publication Critical patent/WO2015079420A2/fr
Publication of WO2015079420A3 publication Critical patent/WO2015079420A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention vise l'utilisation, comme molécule vaccinale chez un mammifère, d'une PSA, telle qu'issue de leishmanie, ou une partie de cette PSA possédant des propriétés immunogènes, ladite PSA désignée ci-après par ES PSAr, se présentant sous forme soluble, native, recombinante. Elle vise également une composition vaccinale pour la prévention et/ou le traitement des leishmanioses comprenant une protéine ES PSAr.
PCT/IB2014/066425 2013-11-29 2014-11-28 Composition vaccinale pour la prevention et/ou le traitement de leishmanioses, peptides immunogenes et procede d'obtention WO2015079420A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP14830587.3A EP3074418A2 (fr) 2013-11-29 2014-11-28 Composition vaccinale pour la prevention et/ou le traitement de leishmanioses, peptides immunogenes et procede d'obtention
BR112016012097-3A BR112016012097A2 (pt) 2013-11-29 2014-11-28 composição vacinal para a prevenção e/ou o tratamento de leishmanioses, peptídeos imunogênicos e processo de obtenção

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR13/61823 2013-11-29
FR1361823A FR3014103B1 (fr) 2013-11-29 2013-11-29 Composition vaccinale pour la prevention et/ou le traitement de leishmanioses, peptides immunogenes et procede d'obtention

Publications (2)

Publication Number Publication Date
WO2015079420A2 WO2015079420A2 (fr) 2015-06-04
WO2015079420A3 true WO2015079420A3 (fr) 2015-11-12

Family

ID=50877363

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/066425 WO2015079420A2 (fr) 2013-11-29 2014-11-28 Composition vaccinale pour la prevention et/ou le traitement de leishmanioses, peptides immunogenes et procede d'obtention

Country Status (4)

Country Link
EP (1) EP3074418A2 (fr)
BR (1) BR112016012097A2 (fr)
FR (1) FR3014103B1 (fr)
WO (1) WO2015079420A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3081870B1 (fr) 2018-05-30 2024-04-19 Institut De Rech Pour Le Developpement Ird Epitopes, composes peptidiques mono-ou multiepitopiques et vaccins contre la leishmanie

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2863272A1 (fr) * 2003-11-19 2005-06-10 Inst Rech Developpement Ird Nouveaux moyens pour la prevention des leishmanioses

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705358B1 (fr) 1993-05-13 1995-08-04 Orstom Procédé de culture in vitro de différents stades de parasites tissulaires, stades parasitaires obtenus et applications biologiques.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2863272A1 (fr) * 2003-11-19 2005-06-10 Inst Rech Developpement Ird Nouveaux moyens pour la prevention des leishmanioses

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JENA BIOSCIENCE: "Leishmania tarentolae Expression Vector NOT INTENDED FOR HUM AN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES", 1 January 2005 (2005-01-01), XP055144855, Retrieved from the Internet <URL:http://ubio.bioinfo.cnio.es/data/crystal/local_info/vectors/pFsat.pdf> [retrieved on 20141007] *
MOHAMMAD SOLEIMANI ET AL: "Expression of human tissue plasminogen activator in the trypanosomatid protozoan Leishmania tarentolae", BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY, vol. 48, no. 1, 1 September 2007 (2007-09-01), pages 55, XP055144853, ISSN: 0885-4513, DOI: 10.1042/BA20060217 *
RACHEL BRAS-GONÇALVES ET AL: "Identification and characterization of new Leishmania promastigote surface antigens, LaPSA-38S and LiPSA-50S, as major immunodominant excreted/secreted components of L. amazonensis and L. infantum", INFECTION, GENETICS AND EVOLUTION, vol. 24, 1 June 2014 (2014-06-01), pages 1 - 14, XP055144869, ISSN: 1567-1348, DOI: 10.1016/j.meegid.2014.02.017 *
RYM CHAMAKH-AYARI ET AL: "In Vitro Evaluation of a Soluble Leishmania Promastigote Surface Antigen as a Potential Vaccine Candidate against Human Leishmaniasis", PLOS ONE, vol. 9, no. 5, 2 May 2014 (2014-05-02), pages e92708, XP055144866, DOI: 10.1371/journal.pone.0092708 *

Also Published As

Publication number Publication date
EP3074418A2 (fr) 2016-10-05
FR3014103A1 (fr) 2015-06-05
BR112016012097A2 (pt) 2020-11-10
FR3014103B1 (fr) 2019-08-16
WO2015079420A2 (fr) 2015-06-04

Similar Documents

Publication Publication Date Title
WO2015061416A3 (fr) Épitopes agonistes de hla-a24 de l&#39;oncoprotéine muc1-c, compositions en contenant et leurs procédés d&#39;utilisation
ZA201900367B (en) Formulation of a peptide vaccine
PH12015501092A1 (en) Anti-ceacam5 antibodies and uses thereof
CA2830786C (fr) Proteines de fusion et polyvaccins comprenant la proteine e et la piline a d&#39;haemophilus influenzae
WO2016070166A3 (fr) Molécules d&#39;una messager et leurs utilisations
EA201691146A1 (ru) Иммуногенное соединение
EP3363458A3 (fr) Peptide
IN2014DN10288A (fr)
WO2014150600A3 (fr) Toxines modifiées
BR112014026531A2 (pt) proteínas de ligação de antígeno ligando cd30 humano
WO2014136064A3 (fr) Polypeptides immunogènes de fusion
WO2015020913A3 (fr) Protéines d&#39;hémagglutinine de la grippe et méthodes associées
WO2008124646A3 (fr) Utilisation de protéines amyloïdes en tant qu&#39;échafaudages pour des vaccins
NZ703597A (en) Mutant fragments of ospa and methods and uses relating thereto
BR112015000585A2 (pt) cepas mutantes de mycoplasma hyopneumoniae
EA201692279A1 (ru) Способ уменьшения иммуногенности белка и пептида
NZ609916A (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
WO2012014073A3 (fr) Vaccins dirigés contre le paludisme lié à la grossesse
NZ602380A (en) Peptides for vaccine against birch allergy
MX363149B (es) Vacunas de nucleoproteina de la influenza.
NZ596501A (en) Casb7439 constructs
WO2015079420A3 (fr) Composition vaccinale pour la prevention et/ou le traitement de leishmanioses, peptides immunogenes et procede d&#39;obtention
WO2014152831A3 (fr) Peptides de ciblage et leurs utilisations
WO2014060851A3 (fr) Compositions immunogènes contre le virus de l&#39;hépatite c et procédés pour l&#39;utiliser
WO2013171661A3 (fr) Formulations d&#39;adjuvant et méthodes associées

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2014830587

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014830587

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14830587

Country of ref document: EP

Kind code of ref document: A2

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016012097

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112016012097

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160527